European Medicines Agency (EMA) commentary on EMA/CHMP Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low‐sized study populations
Authors
Milica Mitrevski
Diana Hartenstein
José Manuel Zubeldia (ORCID: https://orcid.org/0000-0003-3110-274X)
Andreas Bonertz (ORCID: https://orcid.org/0000-0002-6846-9265)
Susanne Kaul
Catherine Drai
Institutions
European Medicines Agency (NL)
Hospital General Universitario Gregorio Marañón (ES)
Centre for Biomedical Network Research on Rare Diseases (ES)
European Medicines Agency (EMA) commentary on EMA/CHMP Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low‐sized study populations
Milica Mitrevski, Diana Hartenstein, José Manuel Zubeldia, Andreas Bonertz et al.
Citations
1 citations
Journal
British Journal of Clinical Pharmacology
Topics
Allergic Rhinitis and Sensitization
Field-Weighted Citation Impact (FWCI)
1.62
article
European Medicines Agency (EMA) commentary on EMA/CHMP Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low‐sized study populations
Milica Mitrevski, Diana Hartenstein, José Manuel Zubeldia, Andreas Bonertz, Susanne Kaul, Catherine Drai
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
British Journal of Clinical PharmacologyVol. 91(5)
Institutions
European Medicines Agency (NL), Hospital General Universitario Gregorio Marañón (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Italian Medicines Agency (IT), Paul Ehrlich Institut (DE)